SBIR · Apr 2021
NIH/HHS Phase I STTR award of $405,552 for an EGFL6 antibody program in platinum-resistant ovarian cancer.
Tradewind translates scientific insight into innovative ways of…
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Bay Area biotechnology company developing first-in-class inhibitory antibody therapeutics for aggressive metastatic cancers, especially late-stage ovarian cancer, with a lead program targeting the secreted protein EGFL6.
Primary product
EGFL6-targeting inhibitory antibody therapeutic for ovarian cancer
Founded
2016
Headquarters
MBC BioLabs, 733 Industrial Rd, San Carlos, CA 94070, United States
Team size
1-10
Industry
Biotechnology
Sub-industry
Oncology drug discovery / therapeutic antibody development
Offices
MBC BioLabs, 733 Industrial Rd, San Carlos, CA 94070
38 Morningside Dr, Daly City, CA 94015-4509, United States
Business model
Preclinical therapeutic antibody development
Grant-funded biotechnology R&D
Future clinical development / partnering
Funding
Stage
Seed / grant-backed
Total raised
$525.6K
Latest round
SBIR Phase I STTR Grant · Apr 2021
Latest amount
$405.6K
Apr 2021 · U.S. Department of Health and Human Services (NIH)
Mar 2018 · Y Combinator
People & investors
Leadership
CEO / Founder
Melanie Finlayson
Chief Business Officer
Scientific Director
Co-Founder / Strategic Advisor
Work & culture
Mission-driven, research-centric biotech focused on transformative therapies for late-stage ovarian and metastatic cancers.
Product & market
Differentiators
- —First-in-class inhibitory antibody approach
- —Targets a secreted protein implicated in metastasis rather than a standard mutated kinase
- —Aims to attack primary tumors and metastatic spread with one therapeutic
- —Potential companion diagnostics / biomarker selection
- —Focus on late-stage ovarian cancer with broader solid-tumor applicability
Technology
Antibody therapeutics
EGFL6 / secreted-protein target biology
Patient-derived xenograft (PDX) models
In vivo mouse models
Biomarker / protein-staining patient selection
Competitors
Jazz Pharmaceuticals
Moderna
Sana Biotechnology
Scale & contact
Estimated revenue
Under $0.5M
Estimated monthly visits
195
Latest news
CEOCFO Interviews · Feb 2019
Interview with Thaddeus Allen on the company's antibody therapeutic, PDX work, companion diagnostics, and broader cancer applicability.
TechCrunch · Mar 2018
Mentions Tradewind BioScience as a cancer-spread blocking biotech focused first on ovarian cancer.
TechCrunch · Mar 2018
Launch coverage describing the company's EGFL6-targeting antibody approach, founders, and early funding expectations.
Jobs and careers at Tradewind BioScience
0 jobs at Tradewind BioScience
No open positions
Check back later for new openings